S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
$3.25
+1.2%
$2.01
$1.56
$3.88
$47.13M1.171.18 million shs218,431 shs
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$4.57
$4.42
$3.03
$10.30
$156.53M1.3288,920 shs77,779 shs
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
$0.04
+34.5%
$0.03
$0.17
$0.89
$1.91M2.974,987 shs950 shs
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
$0.04
+34.5%
$0.03
$0.00
$1.27
$2.46M0.2826,719 shs950 shs
ImmuCell Co. stock logo
ICCC
ImmuCell
$5.03
-0.4%
$5.16
$4.26
$6.05
$38.98M0.597,789 shs2,492 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
-1.83%+2.23%+86.63%+99.38%+60.50%
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
+4.34%+4.34%-0.65%+6.28%-38.08%
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
0.00%0.00%+6.67%-11.93%-51.90%
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
0.00%0.00%+6.67%-11.93%-51.90%
ImmuCell Co. stock logo
ICCC
ImmuCell
0.00%-2.88%+1.20%-5.96%+4.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.5337 of 5 stars
3.52.00.00.03.10.00.6
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
ImmuCell Co. stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/AN/AN/AN/A
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00
Buy$17.25277.46% Upside
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
N/AN/AN/AN/A
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
N/AN/AN/AN/A
ImmuCell Co. stock logo
ICCC
ImmuCell
N/AN/AN/AN/A

Current Analyst Ratings

Latest ABIO, GNWSF, ICCC, ACHV, and GNWSD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
4/1/2024
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
3/5/2024
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $11.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/AN/AN/AN/A$2.89 per shareN/A
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A($0.07) per shareN/A
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
$140K13.63N/AN/A($0.13) per share-0.30
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
$4.15M0.59N/AN/A($0.02) per share-1.95
ImmuCell Co. stock logo
ICCC
ImmuCell
$17.47M2.23N/AN/A$3.23 per share1.56

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
-$5.34M-$0.37N/AN/AN/A-13.80%-13.33%4/22/2024 (Estimated)
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$29.82M-$1.53N/AN/AN/AN/A-936.70%-127.66%5/14/2024 (Estimated)
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
-$3.48MN/A0.00N/A217.39%N/A-61.21%N/A
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
-$6.86M-$0.28N/AN/A-200.26%N/A-165.13%N/A
ImmuCell Co. stock logo
ICCC
ImmuCell
-$5.78M-$0.75N/AN/A-33.05%-21.79%-13.16%5/9/2024 (Confirmed)

Latest ABIO, GNWSF, ICCC, ACHV, and GNWSD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
ImmuCell Co. stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/AN/A  
2/27/2024Q4 2023
ImmuCell Co. stock logo
ICCC
ImmuCell
N/A-$0.15-$0.15-$0.15N/A$5.10 million
2/1/2024Q4 2023
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/A-$0.08-$0.08-$0.08N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/AN/AN/AN/AN/A
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
N/AN/AN/AN/AN/A
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
N/AN/AN/AN/AN/A
ImmuCell Co. stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
N/A
59.01
59.01
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
4.02
0.82
0.82
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
N/A
0.09
0.06
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
N/A
1.15
1.08
ImmuCell Co. stock logo
ICCC
ImmuCell
0.42
2.73
0.87

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ARCA biopharma, Inc. stock logo
ABIO
ARCA biopharma
414.50 million10.02 millionOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
2034.25 million33.57 millionOptionable
StageZero Life Sciences Ltd. stock logo
GNWSD
StageZero Life Sciences
N/A48.94 millionN/ANot Optionable
StageZero Life Sciences Ltd. stock logo
GNWSF
StageZero Life Sciences
5163.00 millionN/ANot Optionable
ImmuCell Co. stock logo
ICCC
ImmuCell
747.75 million7.26 millionNot Optionable

ABIO, GNWSF, ICCC, ACHV, and GNWSD Headlines

SourceHeadline
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average of $5.03ImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average of $5.03
americanbankingnews.com - April 12 at 3:18 AM
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average of $5.03ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average of $5.03
americanbankingnews.com - April 12 at 2:44 AM
ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
finanznachrichten.de - April 10 at 9:38 AM
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
markets.businessinsider.com - April 9 at 7:25 PM
ImmuCell reports preliminary Q1 sales, stock climbs 7%ImmuCell reports preliminary Q1 sales, stock climbs 7%
msn.com - April 9 at 7:25 PM
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
globenewswire.com - April 9 at 4:05 PM
ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call TranscriptImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 29 at 12:41 PM
ImmuCell Corporation (ICCC) Q4 2023 Earnings Call TranscriptImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript
seekingalpha.com - February 28 at 4:23 PM
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
globenewswire.com - February 27 at 4:05 PM
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
finance.yahoo.com - February 16 at 12:18 PM
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
globenewswire.com - February 16 at 9:30 AM
ImmuCell Corporation: Results Of Operations And Financial Condition, Financial Statements And ExhibitsImmuCell Corporation: Results Of Operations And Financial Condition, Financial Statements And Exhibits
cbonds.com - January 10 at 1:04 PM
ImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and DatesImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and Dates
benzinga.com - January 9 at 3:04 PM
ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
finanznachrichten.de - January 9 at 10:04 AM
ImmuCell says total sale for year ended December falls 6% Y/YImmuCell says total sale for year ended December falls 6% Y/Y
msn.com - January 8 at 5:04 PM
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
finance.yahoo.com - January 8 at 5:04 PM
ImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call TranscriptImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 15 at 6:09 PM
ImmuCell Corporation (ICCC) Q3 2023 Earnings Call TranscriptImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript
seekingalpha.com - November 14 at 4:33 PM
ImmuCell GAAP EPS of -$0.12, revenue of $5.39MImmuCell GAAP EPS of -$0.12, revenue of $5.39M
msn.com - November 13 at 7:53 PM
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
finance.yahoo.com - November 13 at 7:53 PM
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
finance.yahoo.com - November 7 at 12:51 PM
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
finance.yahoo.com - October 5 at 7:23 PM
ImmuCell Corporation (ICCC) Stock Historical Prices & Data - Yahoo FinanceImmuCell Corporation (ICCC) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - September 5 at 6:13 PM
ImmuCell Announces Submission of CMC Technical Section to the FDAImmuCell Announces Submission of CMC Technical Section to the FDA
finance.yahoo.com - August 29 at 8:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ARCA biopharma logo

ARCA biopharma

NASDAQ:ABIO
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Achieve Life Sciences logo

Achieve Life Sciences

NASDAQ:ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.
StageZero Life Sciences logo

StageZero Life Sciences

OTCMKTS:GNWSD
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Markham, Canada.
StageZero Life Sciences logo

StageZero Life Sciences

OTCMKTS:GNWSF
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.
ImmuCell logo

ImmuCell

NASDAQ:ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.